Cardiologists share update after world’s first implant of new optimizer device for tricuspid regurgitation

An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.

(A and B) Baseline torrential tricuspid regurgitation; (C and D) computed tomography scan simulation of the TRiFlO device; (E and F) the TRiFlO device consists of 3 anchors and a central tricuspid flow optimizer (TFO); anchors are secured at the commissures and the TFO targets the regurgitant area; (G and H) TFO opens during systole and closes in diastole thus targeting tricuspid regurgitation; (I and J) fluoroscopic imaging of the TRiFlO device positioned and then released; (K) acute procedural result; (L) 6 months’ follow-up demonstrating reverse remodeling of the right ventricle with moderate tricuspid regurgitation. Image and caption courtesy of Ussia et al. and JACC: Cardiovascular Interventions.

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.

Radiologist and 'Doctor Money Matters' podcast host Tarang Patel on why he is hopeful about the specialty's future

Bob Still RBMA 2024

RBMA Executive Director Bob Still (pictured) conducted a live interview with Tarang Patel, MD, at the association's annual meeting in Las Vegas on April 16. 

The noted radiologist discussed what's ahead for the specialty during the closing keynote at RBMA's annual meeting in Las Vegas. 

Design by Adaptive Theme